Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugo Geerts

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Alzheimer'S Research & Therapy|February 4, 2018
Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology modelHugo Geerts, Athan Spiros, Patrick Roberts
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 5, 2021
Exploring the relation between BOLD fMRI and cognitive performance using a computer-based quantitative systems pharmacology model: Applications to the COMTVAL158MET genotype and ketamineHugo Geerts, Patrick Roberts, Athan Spiros
Journal of Alzheimer'S Disease Reports|December 30, 2021
Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer's DiseaseHugo Geerts, Piet van der Graaf
Frontiers in Pharmacology|February 13, 2016
A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's DiseasePatrick Roberts, Athan Spiros, Hugo Geerts
Expert Review of Clinical Pharmacology|July 19, 2018
Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseasesHugo Geerts, Ronald Gieschke, Richard Peck
Frontiers in Pharmacology|November 7, 2014
A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balanceAthan Spiros, Patrick Roberts, Hugo Geerts
Alzheimer'S & Dementia (New York, N. Y.)|November 9, 2020
A modeling informed quantitative approach to salvage clinical trials interrupted due to COVID-19Hugo Geerts, Piet van der Graaf
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 8, 2017
Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loopAthan Spiros, Patrick Roberts, Hugo Geerts
Neuropsychiatric Disease and Treatment|September 22, 2010
Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapseAthan Spiros, Robert Carr, Hugo Geerts
Expert Review of Neurotherapeutics|December 6, 2016
Phosphodiesterase 10 inhibitors in clinical development for CNS disordersHugo Geerts, Athan Spiros, Patrick Roberts
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Alzheimer'S Research & Therapy|February 4, 2018
Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology modelHugo Geerts, Athan Spiros, Patrick Roberts
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 5, 2021
Exploring the relation between BOLD fMRI and cognitive performance using a computer-based quantitative systems pharmacology model: Applications to the COMTVAL158MET genotype and ketamineHugo Geerts, Patrick Roberts, Athan Spiros
Journal of Alzheimer'S Disease Reports|December 30, 2021
Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer's DiseaseHugo Geerts, Piet van der Graaf
Frontiers in Pharmacology|February 13, 2016
A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's DiseasePatrick Roberts, Athan Spiros, Hugo Geerts
Expert Review of Clinical Pharmacology|July 19, 2018
Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseasesHugo Geerts, Ronald Gieschke, Richard Peck
Frontiers in Pharmacology|November 7, 2014
A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balanceAthan Spiros, Patrick Roberts, Hugo Geerts
Alzheimer'S & Dementia (New York, N. Y.)|November 9, 2020
A modeling informed quantitative approach to salvage clinical trials interrupted due to COVID-19Hugo Geerts, Piet van der Graaf
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 8, 2017
Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loopAthan Spiros, Patrick Roberts, Hugo Geerts
Neuropsychiatric Disease and Treatment|September 22, 2010
Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapseAthan Spiros, Robert Carr, Hugo Geerts
Expert Review of Neurotherapeutics|December 6, 2016
Phosphodiesterase 10 inhibitors in clinical development for CNS disordersHugo Geerts, Athan Spiros, Patrick Roberts
Pageof 8